On Thursday, Shares of Merck & Co. Inc. (NYSE:MRK), gained 0.12% to $57.67.
Merck & Co., known as MSD outside the United States and Canada, will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Shares of Maxim Integrated Products, Inc. (NASDAQ:MXIM), inclined 0.17% to $34.56, during its last trading session.
Maxim Integrated Products, will declare fiscal fourth quarter 2015 results after market close on Thursday, July 23, 2015.
A conference call and live webcast will follow at 2:00 p.m. Pacific Time, which can be accessed at www.maximintegrated.com/company/investor. To listen via telephone, dial (866) 804-3547 (toll free) or (703) 639-1328.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs.
Finally, Alere Inc. (NYSE:ALR), ended its last trade with 0.43% gain, and closed at $53.97, hitting its highest level.
Alere Inc., declared that it has accomplished its formerly declared offering of $425 million of senior subordinated notes. The notes will bear interest at a rate of 6.375% per year, payable semi-annually on January 1 and July 1 of each year, starting on January 1, 2016, and will mature on July 1, 2023 unless earlier redeemed. The Company intends to use the net proceeds from the offering to redeem, effective as of October 1, 2015, all of its outstanding $400 million aggregate principal amount of 8.625% senior subordinated notes due 2018 and to pay a portion of related redemption fees, premiums, costs and expenses and accrued interest on such notes. The Company exercised its right away to satisfy and discharge all of its obligations with respect to the 8.625% senior subordinated notes, subject to settlement of the redemption on October 1, 2015. As a result of this refinancing, the Company anticipates to save about $2 million in quarterly interest expense.
The private placement was made to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in reliance on Regulation S under the Securities Act. The notes have not been, and will not be, registered under the Securities Act. Unless so registered, the notes may not be offered or sold in the United States except following an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful preceding to registration or qualification under the securities laws of any such jurisdiction.
Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
